Translational Oncology: Targeted Therapy in Cancer

Targeted Therapy in Translational Cancer Research for the Translational Oncology series provides a comprehensive overview of recent developments in our understanding of tumor biology, elucidates the roles of targets and pathways involved in carcinogenesis, and describes current state–of–the–art anticancer therapy, as well as the most promising areas of translational research and targeted therapy. Introduces cutting–edge bench to bedside and back breakthroughs which have transformed the diagnosis, prognosis, and treatment of cancer Covers basic principles of targeted therapy, including immunotherapy and the roles of cancer stem cells, the microenvironment, angiogenesis, epigenetics, microRNAs, and functional imaging in precision medicine Summarises major advances in therapeutic management of hematologic malignancies and solid tumors using conventional therapy, targeted therapy, immunotherapy, or novel treatment modalities INDICE: List of Contributors .Series Foreword .Foreword .Preface .Part 1: Principles of Targeted Therapies .1 Targeted and Functional ImagingJian Q. (Michael) Yu, Drew A. Torigian, Abass Alavi .2 Combining Targeted TherapiesJordi Rodon, Analia Azaro, Davis Torrejon, Razelle Kurzrock .3 Toward Personalized Therapy for CancerAshley M. Holder, Funda Meric–Bernstam .4 Principles of Targeted ImmunotherapySusanne H.C. Baumeister, Glenn Dranoff .5 Cancer Stem Cell PrinciplesAllison Sharrow, Gabiel Ghiaur, Richard J. Jones .6 The Impact of Genomics on Targeted Therapy in Multiple Myeloma and LymphomasJens G. Lohr and Birgit Knoechel .7 The Tumor Microenvironment as a Target for Therapeutic InterventionHua Fang, Yves A. DeClerck .8 The Role of Angiogenesis in CancerMorgan Taylor, Robert L. Coleman and Anil K. Sood .9 EpigeneticsOmatayo Fasan, Patrick Boland, Patricia Kropf, Jean–Pierre J. Issa .10 The Role of MicroRNAs in CancerGianpiero Di Leva and Carlo M. Croce .Part 2: Targeted Therapy in Hematological Malignancies .11 Acute myelogenous leukemiaRichard Stone, Ofir Wolach .12 Chronic myelogenous leukemiaElias Jabbour and Jorge Cortes .13 Acute lymphocytic leukemiaNitin Jain, Susan O Brien, Farhad Ravandi–Kashani .14 Chronic lymphocytic leukemiaSusan O?Brien and Preetesh Jain .15 Multiple myelomaGiada Bianchi and Kenneth C. Anderson .16 Myelodysplastic syndromeGuillermo Montalbán Bravo, Guillermo García–Manero .17 Lymphoma and Targeted TherapiesSonali M. Smith, Julie M. Vose .Part 3: Targeted Therapy in Solid Tumors .18 Targeted Therapy in Solid Tumors: BrainShiao–Pei Weathers, Barbara J. O Brien, John F. de Groot, W. K. Alfred Yung .19 Targeted Therapy in Solid Tumors: Breast CancerHarold Burstein .20 Targeted Therapy in Solid Tumors: Colorectal CancerScott Kopetz, Maen Abdelrahim, David Menter .21 Targeted Therapy in Solid Tumors: Endometrial CancerJessica L. Bowser, Russell R. Broaddus, Robert L. Coleman, Shannon N. Westin .22 Targeted Therapy in Solid Tumors: Head and NeckMarcus M. Monroe and Jeffrey N. Myers .23 Targeted Therapy in Solid Tumors: Lung cancerSaiama N Waqar, Daniel Morgensztern, Roy S Herbst .24 Targeted Therapy in MelanomaKeith T. Flaherty .25 Targeted Therapy in Solid Tumors: Ovarian cancerShannon N. Westin, Larissa A. Meyer, Robert L. Coleman .26 Molecular Therapeutics: Pancreatic CancerDavid Fogelman, Milind Javle, James Abbruzzese .27 Targeted Therapies for Pediatric Solid TumorsJasmine Quynh Dao, Patrick A. Zweidler–McKay .28 Targeted Therapy in Solid Tumors: Prostate CancerWilliam G. Nelson,  Michael C. Haffner, and Srinivasan Yegnasubramanian .29 Renal Cell Carcinoma and Targeted TherapyBenjamin A. Gartrell, Alexander C. Small, William K. Oh, Matthew D. Galsky .30 Targeted Therapy in Solid Tumors: SarcomaShreyaskumar Patel, Anthony P. Conley,  Vinod Ravi .Part 4: Targeted Therapy for Specific Molecular Aberrations .31 RAS–RAF–MEK pathway: Aberrations and therapeutic possibilitiesJavier Munoz, Filip Janku .32 The Phosphatidylinositol 3–kinase Pathway in Human MalignanciesSamuel J. Klempner, Thanh–Trang Vo, Andrea P. Myers, Lewis C. Cantley .33 Current status and future direction of PARP inhibition in cancer therapySaeed Rafii, Stan Kaye and Susana Banerjee .34 Targeting the c–Met KinaseChad Tang, M. Angelica Cortez, David Hong, James W. Welsh .35 Kit kinaseScott Woodman .36 TP53Michael Andreef and Kensuke Kojima .Part 5: Future Perspectives .37 Future PerspectivesApostalia M. Tsimberidou and Rabih Said .Index

• ISBN: 978-1-118-46857-9
• Editorial: Wiley–Blackwell
• Encuadernacion: Cartoné
• Páginas: 368
• Fecha Publicación: 30/09/2015
• Nº Volúmenes: 1
• Idioma: Inglés